The Science and IP Behind our Treatments

Clearmind’s novel treatment candidates are backed by rigorous science and well-defined intellectual property. Below is a deep dive into the science behind MEAI and the patents that protect it and other treatments.

About MEAI

A Novel Treatment For Addiction

Breaking the Addiction Cycle

MEAI holds the promise to break the vicious binge-drinking cycle by potentially innervating neural pathways such as 5-HT1A, which leads to decreased impulsivity and “sensible behaviour”.

Self-Administered & Limiting

Pre-clinical in vivo results demonstrate longtail tapering off of activity via oral administration. This may explain the self-limiting property of MEAI — unlike traditional treatments.

Widely Applicable

The literature shows that 5-HT1A receptors are associated with controlling craving behaviour across the board. This indicates that MEAI may have a wide range of applications beyond binge drinking.

[After consuming MEAI] I feel intense but controlled euphoria. Now the idea of drinking alcohol seems repulsive—as does eating bar food.


Science of MEAI

Toxicology Studies Show Promising Results

MEAI was progressed through a preliminary drug  development route with a number of studies:

Acute and subacute toxicity evaluated on rats
The interaction of MEAI with ethanol (alcohol)
In-vitro cytotoxic and mutagenic effects

A comparison of the complete blood count values between the treatment  groups (10, 30 and 90mg/kg) to the control group, revealed no significant changes, which indicate a lack of toxicity on the hematopoietic system after 5 days of subacute MEAI exposure.

These results together with the  pathological and histopathological finding indicate lack of liver and kidney toxicities in the subacute toxicity study. The combination of 6% or 7.5% ethanol with 100 mg/L MEAI revealed no  statistically significant increase of cytotoxic effect.


Low Toxicity and a Strong Safety Profile

No Side Effects

5 days oral administration of MEAI (at a dose level of 10 and 30 mg/kg in male  and female rats) did not cause any significant adverse clinical effects.

Low Toxicity

Low cytotoxicity was observedin the in vitro cytotoxicity assays3.

A Good Safety Profile

MEAI showed a good safety profileat 10 and 30mg/kg in rats, corresponding to  the human doses of 1.6 mg/kg and 4.8 mg/kg respectively.

Safe with Alcohol

Ethanol-MEAI mixtures induced no synergistic/additive neurotoxicity.

Shimshoni Jacob1 and Nutt David2, et al. 2017

[1] Kimron Veterinary Institute, Department of Toxicology, Bet Dagan, Israel.

[2] Imperial College London, Neuropsychopharmacology Unit, London, UK.

Our Intellectual Property

Patent-Protected Across the World

Our IP portfolio consists of 18 utility patent families including 27 granted patents. The portfolio spans a wide range of jurisdictions including the US, Europe, India and China.

Links to two of our patent family filings are below.

Alcoholic Beverages Substitutes, and Binge Behaviour Regulators:

27 Granted patents in US, Europe, India, China and more

Combination treatment of Obesity and metabolic syndrome, treatment of cocaine addiction, treatment of binge behaviours, and treatment of depression. Benzufurans as Fail-Safes for MDMA Therapy, 2-FDCK for treatment of depression and TRD, combination treatment of PEA with MDMA, ibogaine, ketamine, LSD, psilocybin and DMT, 3-MMC for treatment of Dyskinesia, 3-MMC for treatment of eating disorders, novel psychedelics, methods of preparation and uses

Pending worldwide


2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and α2-adrenergic receptors.

Adam L. Halberstadt, Simon D. Brandt, Donna Walther, Michael H. Baumann



236, 989-999


Over the last decade, many new psychostimulant analogues have appeared on the recreational drug market and most are derivatives of amphetamine or cathinone. Another class of designer drugs is derived from the 2-aminoindan structural template. Several members of this class, including the parent compound 2-aminoindan (2-AI), have been sold as designer drugs. Another aminoindan derivative, 5-methoxy-2-aminoindan (5-MeO-AI or MEAI), is the active ingredient in a product marketed online as an alcohol substitute.


Pharmacokinetic and pharmacodynamic evaluation of 5-methoxy-2- aminoindane (MEAI): A new binge-mitigating agent.

Jakob A. Shimshoni, Eyal Sobol, Ezekiel Golan, Yulius Ben Ari, Orit Gal


Toxicology and Applied Pharmacology

343, 29-39


5-Methoxy-2-aminoindane (MEAI) is a novel psychoactive aminoindane derivative, exerting euphoric, alcohol-like tipsy experience and reduced desire to consume alcoholic beverages. Our previous toxicological evaluation of MEAI in rats, clearly indicated MEAI's potential to be further evaluated as a promising binge mitigating agent due to its favorable safety profile. In the light of these observations, we have determined MEAI's pharmacokinetic (PK) profile in rats and evaluated in-vitro its pharmacodynamics (PD) profile...


Toxicology and Applied Pharmacology publishes original scientific research of relevance to animals or humans pertaining to the action of chemicals, drugs, or chemically-defined natural products.

Jakob A. Shimshoni, Ilan Winkler, Nir Edery, Ezekiel Golan, René van Wettum, David Nutt


Toxicology and Applied Pharmacology

319, 59-68


5-Methoxy-2-aminoindane (MEAI) is a psychoactive compound of the aminoindane class, which in recent years has been recreationally used by many people, who reported of a mild euphoric, alcohol-like tipsy experience and reduced desire to consume alcoholic beverages. In the light of these observations it was decided to progress MEAI through a preliminary drug development route and evaluate the acute and subacute toxicity of MEAI administrated orally to Sprague Dawley rats, as well as to determine potential in-vitro cytotoxic and mutagenic effects using...


Join Us

Let's Make History


Reason for Inquiry

Thank you for sending your contact information—your details have been received.

Oops! Something went wrong. Please try again.